AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach[1].
Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options[2].
| Parameter | Value |
|---|---|
| NCT Number | NCT04468659 |
| Phase | PHASE3 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Eisai Inc. |
| Enrollment | 1400 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2020-07-14 00:00:00 |
| Completion Date | 2031-01-16 00:00:00 |
| Last Updated | 2026-01-12 00:00:00 |
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[2:1].
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[3].
The Amyloid pathway represents a promising therapeutic target for Alzheimer's disease. This mechanism has been implicated in the disease pathogenesis through extensive preclinical and clinical research. Modulating this pathway may provide disease-modifying effects by addressing one of the core pathological features of Alzheimer's neurodegenerative process[4].
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[5].
Key features of the Phase 3 design include:
The trial is being conducted at multiple centers worldwide, including:
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:
The rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[6].
The AHEAD 3-45 program combines two parallel studies:
A45 Trial (High Amyloid):
A3 Trial (Intermediate Amyloid):
A45 (Elevated Amyloid):
A3 (Intermediate Amyloid):
Preclinical AD represents the earliest phase of Alzheimer's disease pathology, occurring 10-20 years before clinical symptoms appear:
Timeline of Alzheimer's Disease:
─────────────────────────────────────────────────────────
↓ ↓ ↓ ↓
Preclinical Prodromal Mild AD Moderate/
AD MCI Dementia Severe AD
(Years: -20 to -10) (-10 to -5) (0 to +5) (+5 to +10)
Biomarkers:
A+: + A+: + A+: + A+: +
T+: + T+: + T+: +
N+: + N+: +
| Phase | Amyloid (A) | Tau (T) | Neurodegeneration (N) |
|---|---|---|---|
| Normal | - | - | - |
| Preclinical AD | + | - | - |
| Prodromal MCI | + | + | - |
| AD dementia | + | + | + |
Primary endpoints are assessed at 4 years (216 weeks):
| Trial | Intervention | Population | Status |
|---|---|---|---|
| AHEAD 3-45 | Lecanemab | Preclinical AD | Ongoing |
| API APOE4 | CNP520 | Preclinical AD | Terminated |
| GENERATION | CAD106 | Preclinical AD | Discontinued |
If successful, AHEAD 3-45 could support:
Novel therapeutic approaches for neurodegenerative diseases (2024). 2024. ↩︎
[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23). 2023. ↩︎ ↩︎
Amyloid cascade hypothesis: time for a reappraisal (2023). 2023. ↩︎
Mechanism-driven clinical trials in neurodegeneration (2024). 2024. ↩︎
Clinical trial design in neurodegenerative disease (2023). 2023. ↩︎
Future of Alzheimer's disease clinical trials (2024). 2024. ↩︎